MedTrace Logo

Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes

NCT01647542 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 393

Last updated 2015-11-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and safety of TAK-875 in Asia Pacific adults with type 2 diabetes mellitus (T2DM).

Conditions

Interventions

DRUG

TAK-875

TAK-875 tablets

DRUG

TAK-875 Placebo

TAK-875 placebo-matching tablets

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2014-02-28
Completion
2014-03-31

Countries

  • Australia
  • China
  • New Zealand
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01647542 on ClinicalTrials.gov